Despite the ever-expanding clinical evaluation
of molecularly targeted anticancer agents, little progress has been made in
preventing metastases, the leading cause of death in patients with cancer. Although
there has been some success in controlling tumor growth, this has not
translated in achieving favorable overall survival outcomes. Patricia Steeg,
PhD, from the National Cancer Institute (NCI), suggests that the FDA could spur
initiation of trials with drugs designed to prevent metastases by considering a
delay of cancer spread as a satisfactory endpoint for approval
Source: “Perspective: The right
trials.” Steeg PS. Nature. 2012 May 30;485(7400):S58-9.
Free paper available at:
Aucun commentaire:
Enregistrer un commentaire